Evidence map›Paper›PMID 28718760›Full record

Trial reportLeukemia & lymphoma2018

CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

John N Allan, Gail J Roboz, Gulce Askin, Ellen Ritchie, Joseph Scandura, Paul Christos, Duane C Hassane, Monica L Guzman

Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase IIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.Cancer biomarkers : section A of Disease markers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

John N Allana Department of Medicine, Division of Hematology and Medical Oncology , Weill Cornell Medicine , New York , NY , USA.
Gail J Roboza Department of Medicine, Division of Hematology and Medical Oncology , Weill Cornell Medicine , New York , NY , USA.
Gulce Askinb Department of Healthcare Policy and Research, Division of Biostatistics and Epidemiology , Weill Cornell Medicine , New York , NY , USA.
Ellen Ritchiea Department of Medicine, Division of Hematology and Medical Oncology , Weill Cornell Medicine , New York , NY , USA.
Joseph Scanduraa Department of Medicine, Division of Hematology and Medical Oncology , Weill Cornell Medicine , New York , NY , USA.
Paul Christosb Department of Healthcare Policy and Research, Division of Biostatistics and Epidemiology , Weill Cornell Medicine , New York , NY , USA.
Duane C Hassanea Department of Medicine, Division of Hematology and Medical Oncology , Weill Cornell Medicine , New York , NY , USA.
Monica L Guzmana Department of Medicine, Division of Hematology and Medical Oncology , Weill Cornell Medicine , New York , NY , USA.
Cornell University · USWeill Cornell Medicine · US

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AMLR01CA102031 · NCI · OHIO STATE UNIVERSITY · PI GUZMAN, MONICA L, MARCUCCI, GUIDO · 2004 to 2017
$3.8M
Biomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9M
NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384NCI NIH HHS R01 CA102031NCI NIH HHS R01 CA172546
6 · The paper itself

Abstract

We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25

Indexed as

AgedAged, 80 and overAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBenzylaminesBone MarrowCyclamsDecitabineDNA MethylationDrug Resistance, NeoplasmFemaleHeterocyclic CompoundsHumansInterleukin-2 Receptor alpha SubunitLeukemia, Myeloid, AcuteMaleBenzylaminesCyclamsDecitabineHeterocyclic CompoundsIL2RA protein, humanInterleukin-2 Receptor alpha SubunitplerixaforTP53 protein, humanTumor Suppressor Protein p53AMLCD25decitabinedrug resistanceprognostication

Identifiers

PMID28718760
PMCPMC5773411
OpenAlexW2738550771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.